TY - JOUR
T1 - Effects of honey supplementation on safety profiles among postmenopausal breast cancer patients
AU - Zakaria, Zaida
AU - Zainal Abidin, Zairos F.
AU - Gan, Siew H.
AU - Wan Abdul Hamid, Wan Z.
AU - Mohamed, Mahaneem
N1 - Funding Information:
The researchers would like to acknowledge Research University Grant, Universiti Sains Malaysia (No. 1001/PPSP/853005 ) for funding this study and Hospital Universiti Sains Malaysia for providing the patients for this study.
Publisher Copyright:
© 2018 The Authors
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/12
Y1 - 2018/12
N2 - Objectives: In this study, we aimed to determine the effect of honey supplementation on the safety profiles of postmenopausal breast cancer patients. Methods: Seventy-two postmenopausal women with stage I, II, or III breast cancer from the Oncology Clinic, Universiti Sains Malaysia Hospital were treated with anastrozole (1 mg/day). Patients were randomly assigned to one of the two groups (n = 36/group): a control group (no honey) and a honey group (20 g/day of honey for 12 weeks). Fasting blood samples were obtained pre- and post-intervention to investigate differences in the haematological, renal, and liver profiles of patients in both the groups. Results: Post-intervention, alanine aminotransferase levels were significantly higher in the control group than in the honey group. In the honey group, white blood cell counts, platelet counts, and creatinine levels were significantly higher following honey supplementation for 12 weeks. Nevertheless, the values were still within normal ranges. Conclusions: The present study suggests that honey supplementation of 20 g/day for 12 weeks is safe and beneficial for postmenopausal breast cancer patients.
AB - Objectives: In this study, we aimed to determine the effect of honey supplementation on the safety profiles of postmenopausal breast cancer patients. Methods: Seventy-two postmenopausal women with stage I, II, or III breast cancer from the Oncology Clinic, Universiti Sains Malaysia Hospital were treated with anastrozole (1 mg/day). Patients were randomly assigned to one of the two groups (n = 36/group): a control group (no honey) and a honey group (20 g/day of honey for 12 weeks). Fasting blood samples were obtained pre- and post-intervention to investigate differences in the haematological, renal, and liver profiles of patients in both the groups. Results: Post-intervention, alanine aminotransferase levels were significantly higher in the control group than in the honey group. In the honey group, white blood cell counts, platelet counts, and creatinine levels were significantly higher following honey supplementation for 12 weeks. Nevertheless, the values were still within normal ranges. Conclusions: The present study suggests that honey supplementation of 20 g/day for 12 weeks is safe and beneficial for postmenopausal breast cancer patients.
KW - Breast cancer
KW - Honey
KW - Postmenopausal women
KW - Safety profiles
UR - http://www.scopus.com/inward/record.url?scp=85052743491&partnerID=8YFLogxK
U2 - 10.1016/j.jtumed.2018.04.013
DO - 10.1016/j.jtumed.2018.04.013
M3 - Article
C2 - 31435374
AN - SCOPUS:85052743491
VL - 13
SP - 535
EP - 540
JO - Journal of Taibah University Medical Sciences
JF - Journal of Taibah University Medical Sciences
SN - 1658-3655
IS - 6
ER -
